Surge Of FDA Activity Caps Quiet Year Of Promo Discipline
The U.S. Food and Drug Administration on Friday released a letter chastising Dara Biosciences Inc. for allegedly overstating the benefits and downplaying the risks of cancer drug Soltamox, joining a recent...To view the full article, register now.
Already a subscriber? Click here to view full article